All the news Showing 10 of 72 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Liver cancer risk will remain elevated for people with cirrhosis cured of hepatitis C Keith Alcorn / 16 November 2015 The burden of liver cancer and cirrhosis caused by hepatitis C is likely to continue to grow in the United States despite curative treatment for hepatitis C, and people who have cirrhosis ... HIV Drugs Provide Added Benefit of Protecting Against Hepatitis B Virus Johns Hopkins Medicine / 13 October 2015 Dr. E Lebovics: Post-EASL 2015 HCV Interview American Journal of Medicine Hepatitis C Resource Center / 02 June 2015 Prenylation inhibitor lonafarnib lowers hepatitis delta viral load during therapy Liz Highleyman / 22 May 2015 Lonafarnib, a farnesyl transferase inhibitor that interferes with viral assembly, reduced hepatitis delta virus (HDV) levels by more than 3 log10 in a phase 2 study presented at the European Association for ... Statin use associated with lower risk of liver decompensation and death in hepatitis C patients with cirrhosis Liz Highleyman / 19 May 2015 People with hepatitis and liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of ... Nucleic acid polymer REP 2139-Ca shows promising activity against hepatitis B and hepatitis delta Liz Highleyman / 15 May 2015 The nucleic acid-based polymer REP 2139-Ca lowered hepatitis B surface antigen (HBsAg) levels and significantly reduced hepatitis B and hepatitis delta viral loads when combined with immunotherapy, according to presentations at the European ... Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants Liz Highleyman / 29 April 2015 An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced liver cirrhosis and 94% for ... Alcohol misuse the strongest predictor of severe liver damage and death in French people with hepatitis C Keith Alcorn / 28 April 2015 People with hepatitis C have a much greater risk of liver-related hospitalisation or death if they have an alcohol use disorder or another serious co-morbidity such as HIV infection, chronic kidney disease ... Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis Liz Highleyman / 12 November 2014 An oral regimen of sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation ... Prolonged pegylated interferon plus tenofovir does not prevent hepatitis delta relapse Liz Highleyman / 23 April 2014 Treating hepatitis B patients with hepatitis delta virus (HDV) co-infection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side-effects are frequent and it did not significantly improve ... ← Prev1...34567...8Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive